The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain

European Journal of Pharmacology

Volumn 651, Issue 1-3, 2011, Pages 51-58

  Haduch, Anna ^a   Bromek, Ewa ^a   Daniel, Władysława A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

(Rat CYP2D); Antidepressant; Brain and liver microsome; cDNA expressed CYP2D; Chronic treatment; Neuroleptic

Indexed keywords

CLOZAPINE; CYTOCHROME P450 2D; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PERAZINE; THIORIDAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; BRAIN LEVEL; BRAIN MICROSOME; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER MICROSOME; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BRAIN; CLONING, MOLECULAR; DNA, COMPLEMENTARY; HYDROXYLATION; ISOENZYMES; MALE; MICROSOMES, LIVER; ORGAN SPECIFICITY; RATS; RATS, WISTAR; TIME FACTORS;

EID: 78650677482     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.077     Document Type: Article

References (69)

1. P. Baumann, J.W. Meyer, M. Amey, D. Baettig, C. Bryois, M. Jonzier-Perey, L. Koeb, C. Monney, and B. Woggon Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline Ther. Drug Monit. 14 1992 1 8
2. E. Bromek, A. Haduch, and W.A. Daniel The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: an in vitro study Eur. J. Pharmacol. 626 2010 171 178
3. Caccia S., Cappi M., Fracasso C., and Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat Psychopharmacology 100 1990 509 514
4. S.J. Chinta, H.V. Pal, S.C. Upadhya, M.R. Boyd, and V. Ravindranath Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain Brain Res. Mol. Brain Res. 103 2002 49 61
5. P.J. Cowen Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol. Sci. 29 2008 433 436
6. Daniel W.A. Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 65 73
7. W.A. Daniel The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms Expert Opin. Drug Metab. Toxicol. 1 2005 203 217
8. W.A. Daniel, A. Adamus, M. Melzacka, J. Szymura, and J. Vetulani Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages Naunyn-Schmiedeberg's Arch. Pharmacol. 317 1981 209 213
9. W.A. Daniel, M. Syrek, A. Haduch, J. Wójcikowski, and J. Boksa Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment Pol. J. Pharmacol. 49 1997 439 452
10. W.A. Daniel, M. Syrek, A. Haduch, and J. Wójcikowski Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats J. Pharm. Pharmacol. 52 2000 1473 1481
11. W.A. Daniel, M. Syrek, A. Haduch, and J. Wójcikowski Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants Br. J. Pharmacol. 131 2000 287 295
12. W.A. Daniel, J. Wójcikowski, and A. Pałucha Distribution of psychotropic drugs in the grey and white matter of the brain. In vitro studies Br. J. Pharmacol. 134 2001 807 814
13. W.A. Daniel, A. Haduch, and J. Wójcikowski Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants J. Pharm. Pharmacol. 54 2002 1545 1552
14. W.A. Daniel, A. Haduch, and J. Wójcikowski Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo - possible involvement of different mechanisms Eur. Neuropsyhopharmacol. 15 2005 103 110
15. F. Dutheil, S.D. Dauchy, M. Diry, V. Sazdovitch, O. Cloarec, L. Mellottée, I. Bièche, M. Ingelman-Sundberg, J.-P. Flinois, I. De Waziers, P. Beaune, X. Declèves, C. Duyckaerts, and M.-A. Loriot Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function Drug Metab. Dispos. 37 2009 1528 1538
16. M. Dziedzicka-Wasylewska, Z. Rogóż, W. Margas, D. Dlaboga, and M. Góralska Some behavioural effects of antidepressant drugs are time-dependent Prog. Neuropsychopharmacol. Biol. Psychiatry 25 2001 373 393
17. Y. Funae, W. Kishimoto, T. Cho, T. Niwa, and T. Hiroi CYP2D in the brain Drug Metab. Pharmacokinet. 18 2003 337 349
18. F.J. Gonzalez, R.C. Skoda, S. Kimura, M. Umeno, U.M. Zanger, D.W. Nebert, H.V. Gelboin, J.P. Hardwick, and U.A. Meye Characterization of the common genetic effect in humans deficient in debrisoquine metabolism Nature 331 1988 442 446
19. P.J. Goodnick Pharmacokinetic optimization of therapy with newer antidepressants Clin. Pharmacokinet. 27 1994 307 330
20. A. Haduch, E. Bromek, M. Kot, K. Jemnitz, Z. Veres, L. Vereczkey, and W.A. Daniel Effect of mirtazapine on the CYP2D activity in the primary culture of rat hepatocytes Pharmacol. Rep. 58 2006 979 984
21. T. Hansson, C. Von Bahr, M. Marklund, J.-O. Svensson, M. Ingelman-Sundberg, and J. Lundstrōm Different regiospecificity in the hydroxylation of the antidepressant desmethylimipramine between rat brain and liver Pharmacol. Toxicol. 71 1992 416 419
22. E. Hedlund, A. Wyss, T. Kainu, M. Backlund, C. Kohler, M. Pelto-Huikko, J.A. Gustafsson, and M. Warner Cytochrome P4502D4 in the rat brain: specific neuronal regulation by clozapine and toluene Mol. Pharmacol. 50 1996 342 350
23. T. Hiroi, S. Imaoka, T. Chow, and Y. Funae Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR Biochim. Biophys. Acta 1380 1998 305 312
24. T. Hiroi, S. Imaoka, and Y. Funae Dopamine formation from tyramine by CYP2D6 Biochem. Biophys. Res. Commun. 249 1998 838 843
25. T. Hiroi, W. Kishimoto, T. Chow, S. Imaoka, T. Igarashi, and Y. Funae Progesterone oxidation by cytochrome P450 2D isoforms in the brain Endocrinology 142 2001 3901 3908
26. T. Hiroi, T. Chow, S. Imaoka, and Y. Funae Catalytic specificity of CYP2D isoforms in rat and human Drug Metab. Dispos. 30 2002 970 976
27. J.I. Javaid Clinical pharmacokinetics of antipsychotics J. Clin. Pharmacol. 34 1994 286 295
28. H. Kawashima, D.J. Sequeira, D.R. Nelson, and H.W. Strobel Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18* catalyzing imipramine N-demethylation J. Biol. Chem. 271 1996 28176 28180
29. S. Kimura, M. Umeno, R.C. Skoda, U.A. Meyer, and F.J. Gonzalez The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene Am. J. Hum. Genet. 45 1989 889 904
30. W. Kishimoto, T. Hiroi, M. Shiraishi, M. Osada, S. Imaka, S. Kominami, T. Igarashi, and Y. Funae Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain Endocrinology 145 2004 699 705
31. 2A receptor occupancy Eur. J. Pharmacol. 591 2008 136 141
32. M. Komori A novel P450 expressed at the high level in rat brain Biochem. Biophys. Res. Commun. 196 1993 721 728
33. J. Maj, and A. Moryl Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists Eur. Neuropsychopharmacol. 3 1993 85 94
34. J. Maj, L. Baran, K. Bigajska, Z. Rogóż, and G. Skuza The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan Pol. J. Pharmacol. Pharm. 30 1978 431 440
35. A. Mann, S. Miksys, A. Lee, D.C. Mash, and R.F. Tyndale Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment Neuropharmacology 55 2008 1147 1155
36. J.M. Margolis, and R.S. Obach Impact of nonspecific binding to microsomes and phospholipids on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug metabolism Drug Metab. Dispos. 31 2003 606 611
37. E. Matsunaga, U.M. Zanger, J.P. Hardwick, H.V. Gelboin, U.A. Meyer, and F.J. Gonzales The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats Biochemistry 28 1989 7349 7355
38. E. Matsunaga, M. Uemo, and F.J. Gonzales The rat P450 IID subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme-binding region of the cytochrome P450 active site J. Mol. Evol. 30 1990 155 169
39. M.C. Mauri, L.S. Volonteri, A. Colasanti, A. Florentini, I.F. De Gaspari, and S.R. Bareggi Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response Clin. Pharmacokinet. 46 2007 359 388
40. S.L. Miksys, and R.F. Tyndale Drug-metabolizing cytochrome P450s in the brain J. Psychiatry Neurosci. 27 2002 406 415
41. S. Miksys, and R.F. Tyndale The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics Drug Metab. Rev. 36 2004 313 333
42. S. Miksys, Y. Rao, E.M. Sellers, M. Kwan, D. Mendis, and R.F. Tyndale Regional and cellular distribution of CYP2D subfamily members in rat brain Xenobiotica 30 2000 547 564
43. M. Moor, U.E. Honegger, and U.N. Wiesmann Organ-specific, qualitative changes in the phospholipid composition of rats after chronic administration of the antidepressant drug desipramine Biochem. Pharmacol. 37 1988 2035 2039
44. R. Muscat, M. Papp, and P. Willner Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotyline Psychopharmacology 109 1992 433 438
45. T. Niwa, K. Okada, T. Hiroi, S. Imaoka, S. Narimatsu, and Y. Funae Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain Biol. Pharm. Bull. 31 2008 348 351
46. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients Am. J. Psychiatry 152 1995 1444 1449
47. R.S. Obach The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations Drug Metab. Dispos. 24 1996 1047 1049
48. G.I. Papakostas Dopaminergic-based pharmacotherapies for depression Eur. Neuropsychopharmacol. 16 2006 391 402
49. G. Pinna, E. Costa, and A. Guidotti Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteriod content at doses that are inactive on 5-HT reuptake Psychopharmacology 186 2006 362 372
50. E. Romeo, A. Strōhle, G. Spalletta, F. di Michele, B. Hermann, F. Holsboer, A. Pasini, and R. Rupprecht Effects of antidepressant treatment on neuroactive steroids in major depression Am. J. Psychiatry 155 1998 910 913
51. D.J. Sequeira, and H.W. Strobel In vitro metabolism of imipramine by brain microsomes: effects of inhibitors and endogenous cytochrome P450 reductase Brain Res. 738 1996 24 31
52. H.N. Shahabi, D.R. Andersson, and H. Nissbrandt Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production Synapse 62 2008 379 388
53. J.G. Shin, N. Soukhova, and D.A. Flockhar Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6 Drug Metab. Dispos. 27 1999 1078 1084
54. I. Siegle, P. Frotz, K. Eckhardt, U.M. Zanger, and M. Eichelbaum Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain Pharmacogenetics 11 2001 237 245
55. A. Strōhle, E. Romeo, B. Hermann, A. Pasini, G. Spaletta, F. Di Michele, F. Holsboer, and R. Rupprecht Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery Biol. Psychiatry 45 1999 274 277
56. A. Strōhle, A. Pasini, E. Romeo, B. Hermann, G. Spalletta, F. di Michele, F. Holsboer, and R. Rupprecht Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxy corticosterone (THDOC) in major depression J. Psychiatr. Res. 34 2000 183 186
57. C.M. Thompson, H. Kawashima, and H.W. Strobel Isolation of partially purified P450 2D18 and characterization of activity toward the tricyclic antidepressants imipramine and desipramine Arch. Biochem. Biophys. 359 1998 115 121
58. C.M. Thompson, J.H. Capdevila, and H.W. Strobel Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid J. Pharmacol. Exp. Ther. 294 2000 1120 1130
59. R.F. Tyndale, Y. Li, N.-Y. Li, E. Messina, S. Miksys, and E.M. Sellers Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan Drug Metab. Dispos. 27 1999 924 930
60. D.P. Uzunov, T.B. Cooper, E. Costa, and A. Guidotti Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography Proc. Natl Acad. Sci. USA 93 1996 12599 12604
61. V. Uzunova, Y. Sheline, J.M. Davis, A. Rasmusson, D.P. Uzunov, E. Costa, and A. Guidotti Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine Proc. Natl Acad. Sci. USA 95 1998 3239 3244
62. K. Venkatakrishnan, L.L. von Moltke, R.S. Obach, and D.J. Greenblatt Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro J. Pharmacol. Exp. Ther. 293 2000 343 350
63. P. Voirol, M. Jonzier-Perey, F. Porchet, M.J. Reymond, R.C. Janzer, C. Bouras, H.W. Strobel, M. Kosel, C.B. Eap, and P. Baumann Cytochrome P-450 activities in human and rat brain microsomes Brain Res. 855 2000 235 243
64. M. Warner, and J.A. Gustafsson Effect of ethanol on cytochrome P450 in the rat brain Proc. Natl Acad. Sci. USA 91 1994 1019 1023
65. P. Willner Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation Psychopharmacology 134 1997 319 329
66. A. Wyss, J.-Å. Gustafsson, and M. Warner Cytochromes P450 of the 2D subfamily in rat brain Mol. Pharmacol. 47 1995 1148 1155
67. S. Yadav, A. Dhawan, P.K. Seth, R.L. Singh, and D. Parmar Cytochrome P4503A: evidence for mRNA expression and catalytic activity in rat brain Mol. Cell. Biochem. 287 2006 91 99 (Pubitemid 44057396)
68. A.-M. Yu, J.R. Idle, L.G. Byrd, K.W. Krausz, A. Küpfer, and F.J. Gonzalez Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6 Pharmacogenetics 13 2003 173 181
69. J. Yue, S. Miksys, E. Hoffmann, and R.F. Tyndale Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course J. Psychiatry. Neurosci. 33 2008 54 63